Impact BioMedical (IBO) Q4 2024 earnings summary

Executive summary

• Impact BioMedical completed its IPO in September 2024, raising $3.7M to accelerate R&D and commercialization efforts.

• The company focuses on biopharmaceuticals, consumer wellness, and drug discovery, leveraging a robust IP portfolio and strategic partnerships.

• No revenue was generated in 2024 or 2023; the business remains pre-revenue, with future income expected from licensing and royalties.

• 2024 saw significant IP expansion, debt restructuring, and the first human study for Equivir, targeting a 2025-2026 product launch.

• Operations are conducted through subsidiaries, with a single business segment focused on biotechnology.

Financial highlights

• Net loss for 2024 was $24.8M, compared to $4.4M in 2023, driven by a $25.1M goodwill impairment.

• Total costs and expenses rose 614% year-over-year to $28.8M, mainly due to impairment charges and increased SG&A and marketing costs.

• R&D expenses decreased 84% to $278K as cost-cutting measures were implemented.

• Cash and cash equivalents at year-end 2024 were $2.0M, up from $1K in 2023, reflecting IPO proceeds and new borrowings.

• The company restructured its long-term debt, reducing cash outflows by enabling equity repayment for 24 months.

Outlook and guidance

• Management plans to monetize intellectual property and tightly control costs to support ongoing operations.

• Equivir is expected to launch in the U.S. for the 2025-2026 cold and flu season, pending successful study results.

• The company continues to seek partners for commercialization of Laetose and 3F technologies.

• Substantial doubt remains about the company's ability to continue as a going concern without additional capital or revenue generation.